Analyst Upgrades

• Piper Jaffray upgraded Edwards Lifesciences (EW) to overweight from neutral and raised its target price for shares to $77 from $53 after The New England Journal of Medicine reported the company's PARTNER Trial met primary endpoints.
• UBS upgraded Endo Pharmaceuticals (ENDP) to buy from neutral and raised its price target to $36 from $25. UBS is positive on Endo's creative strategic deals and believes the switch to Opana TRF from Opana ER will be easy. Additionally, the analyst believes pipeline expectations are very low.
• BMO Capital upgraded Nvidia (NVDA) to outperform from market perform based on expectations that share loss in the core GPU business will stop, Tegra momentum and valuation. The firm raised its price target to $16 from $9.
• FirstEnergy (FE) and Allegheny Energy (AYE) were upgraded to outperform from neutral at Credit Suisse.
• Mylan (MYL) was upgraded to conviction buy from buy at Goldman. Warner
• Chilcott (WCRX) was upgraded to overweight from equal weight at Morgan Stanley.

Here are some highlights from this past week's earnings coverage from BloggingStocks:

• Bristol-Myers Squibb Co. (NYSE: BMY) Q1 profit fell despite strong sales of Plavix and Abilify.
• Check Point Software Technologies Inc. (NASDAQ: CHKP) was downgraded based on its guidance.
• Domino's Pizza Inc. (NYSE: DPZ) strong Q1 results were boosted by early debt retirement.
• DreamWorks Animation SKG Inc. (NYSE: DWA) strong Q1 results were driven by Madagascar 2.
• Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP) Q1 results led to an analyst's downgrade.
• E*Trade Financial Corp. (NASDAQ: ETFC) widened its Q1 loss, sending shares sharply lower.

MOST NOTEWORTHY: NutriSystem, Endo Pharmaceuticals, Corporate Express NV, Aventine Renewable Energy Holdings and BioFuel Energy were today's noteworthy downgrades:

• NutriSystem (NASDAQ: NTRI) was downgraded to Hold from Buy at Lazard and to Buy from Strong Buy at Broadpoint following its lowered Q3 guidance.
  
• Jefferies downgraded shares of Endo Pharmaceuticals (NASDAQ: ENDP) to Hold from Buy after Impax Laboratories (NASDAQ: IPXL) filed a Paragraph IV challenge against Opana ER yesterday to reflect the potential for a generic version of Opana ER arriving as early as 2010 and the possibility of a similar threat against Lidoderm.
  
• Corporate Express (NYSE: CXP) was downgraded to Hold from Buy at ING, as they believe the new CEO's long-term targets are overly ambitious.
  
• JP Morgan downgraded Aventine Renewable (NYSE: AVR) and BioFuel Energy (NASDAQ: BIOF) to Neutral from Overweight, citing weaker fundamentals in ethanol pricing.

OTHER DOWNGRADES:

• JP Morgan downgraded Charlotte Russe (NASDAQ: CHIC) and The Wet Seal (NASDAQ: WTSLA) to Neutral from Overweight.
  
• Goldman downgraded Monolithic Power Systems (NASDAQ: MPWR) and Hansen Natural (NASDAQ: HANS) to Neutral from Buy; Goldman removed National Semiconductor (NYSE: NSM) from its Conviction Buy List.

Monday August 13

• Sysco Corporation (NYSE: SYY) to report Q4 earnings; conference call at 9:45am.
• PDUFA date for Indevus Pharmaceuticals Inc's (NASDAQ: IDEV) Sanctura XR, an overactive bladder drug.

Tuesday August 14

• The Home Depot Inc (NYSE: HD) to report Q2 earnings; conference call at 9am. Home Depot is expected to post substantial Q2 revenue/EPS declines, but equally important will be the company's comments: with the housing sector expected to remain sluggish through at least late 2007, analysts will evaluate whether HD can overcome that headwind with a new focus on customer service, demographic trends that suggest increased home repair/remodeling, and 20-year high homeownership rates that suggest steady house goods demand.
• District Court California: Broadcom Corporation (NASDAQ: BRCM) to request an injunction related to Qualcom Incorporated's (Nasdaq: QCOM) infringement of 3 Broadcom cellular baseband patents.

Wednesday August 15

• Macy's Inc (NYSE: M) to report Q2 earnings; conference call at 10:30am.
• PDUFA date for GPC Biotech's (NASDAQ: GPCB) Satraplatin for treatment of hormone refractory prostate cancer.

Thursday August 16

• JC Penney Co Inc (NYSE: JCP) to report Q2 earnings; conference call at 9:30am.
• Hewlett Packard Company (NYSE: HPQ) to report Q3 earnings; conference call at 5pm. Analysts will evaluate HPQ's ability to maintain momentum in its innovative imaging/printing group, which is expected to help HPQ post solid Q3 revenue gains.

Friday August 17

• Quantum Corporation (NYSE: QTM) to hold annual shareholder meeting at 12pm.
• PDUFA Date for Endo Pharmaceuticals Holdings Inc's (NASDAQ: ENDP) and Vernalis PLC's (OTC: VNLSY) Frova, for menstrually-related migraine headaches.

MOST NOTEWORTHY: Dendreon Corp (DNDN), Cubic Corp (CUB), Endo Pharmaceuticals (ENDO), Northrop Grumman (NOC) and Royal Dutch Shell (RDS.A) were today's notable downgrades:

• JMP Securities downgraded shares of Dendreon Corp (NASDAQ: DNDN) to Market Underperform from Market Perform based on the company's uncertain product pipeline and the recent SEC filing that revealed that certain officers and directors are facing potential shareholder lawsuits regarding trading activities.
  

• Friedman Billings cut Cubic Corp (AMEX: CUB) to Underperform from Market Perform on valuation.

• RBC Capital downgraded Endo Pharmaceuticals (OTCBB: ENDP) to Sector Perform from Outperform following the company's withdrawal of guidance pertaining to its NDA for the Ketoprofen patch.

• Northrop Grumman (NYSE: NOC) was cut to Neutral from Overweight at JP Morgan on valuation. UBS cut Royal Dutch Shell to Neutral from Buy on valuation...

OTHER DOWNGRADES:

• Robinson Humphries downgraded Ruby Tuesday (NYSE: RT) to Neutral from Buy.

• Montgomery downgraded shares of Taleo Corp (NASDAQ: TLEO) to Hold from Buy.

• Credit Suisse downgraded AutoZone (NYSE: AZO) to Neutral from Outperform.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).

MOST NOTEWORTHY: Endo Pharmaceuticals Holdings Inc (ENDP) and Coldwater Creek (CWTR) were today's most notable initiations:

• First Albany initiated Endo Pharmaceuticals Holdings Inc (NASDAQ: ENDP) with a Strong Buy rating and $41.25 target; the firm believes the company's strong balance sheet can be used to strengthen the pipeline through the acquisition of product rights or companies.

• Thomas Weisel started Coldwater Creek Inc (NASDQ: CWTR) with an Underperform rating based on the fourth-quarter miss, and believes appreciation could be limited here.

OTHER INITIATIONS:

• Yamana Gold Inc (NYSE: AUY) was initiated with a Sector Performer rating and $20 target at CIBC, explaining that Yamana's production profile is expected to expand by 150% in the next two years, making it one of the fastest-growing gold companies in North America.

• Oppenheimer considers PF Chang's China Bistro's (NASDAQ: PFCB) valuation attractive and started the restaurant chain with a Buy rating and $53 target.

Analyst summaries provided by TheFlyOnTheWall.com (subscription required).